Alan Ashworth, PhD
Professor
Medicine
School of Medicine

Education & Training

Show all (2) Hide

• PhD Biochemistry University College London 1984
• BSc (Hons) Chemistry and Biochemistry Imperial College of Science and Technology, University of London 1981

Grants and Projects

Show all (2) Hide

• DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications, NIH, 2018-2023
• Cancer Center Support Grant, NIH, 1999-2023

Publications (347)

Top publication keywords:
Breast NeoplasmsCyclin-Dependent KinasesEnzyme InhibitorsDNA RepairSynthetic Lethal MutationsBRCA2 ProteinGenes, BRCA1BRCA1 ProteinPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesRNA InterferenceNeoplasmsPhthalazinesGenes, BRCA2Piperazines

• Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy.
  Cancer discovery 2024 Choudhury A, Cady MA, Lucas CG, Najem H, Phillips JJ, Palikuqi B, Zakimi N, Joseph T, Birrueta JO, Chen WC, Oberheim Bush NA, Hervey-Jumper SL, Klein OD, Toedebusch CM, Horbinski CM, Magill ST, …
• Histone demethylase enzymes KDM5A and KDM5B modulate immune response by suppressing transcription of endogenous retroviral elements.
  bioRxiv : the preprint server for biology 2024 Chen H, Sarah L, Pucciarelli D, Mao Y, Diolaiti ME, Fujimori DG, Ashworth A
• Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, Mikayelyan M, Delavan H, Swinderman J, Wilson C, Zhu J, Das R, Nguyen M, Loehr A, Golsorkhi T, Simmons A, Abida W, Chinnaiyan AM, Arkin MR, …
• PARP7 Inhibitors and AHR Agonists Act Synergistically Across a Wide-Range of Cancer Models.
  Molecular cancer therapeutics 2024 Chen H, Gou X, Mao Y, O'Leary PC, Diolaiti ME, Ashworth A
• The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2.
  bioRxiv : the preprint server for biology 2024 Suryawanshi RK, Jaishankar P, Correy GJ, Rachman MM, O'Leary PC, Taha TY, Zapatero-Belinchón FJ, McCavittMalvido M, Doruk YU, Stevens MGV, Diolaiti ME, Jogalekar MP, Richards AL, Montano M, Rosecrans …

Show all (342 more) Hide

• AcrIF11 is a potent CRISPR-specific ADP-ribosyltransferase encoded by phage and plasmid.
  bioRxiv : the preprint server for biology 2024 Chen DF, Roe LT, Li Y, Borges AL, Zhang JY, Babbar P, Maji S, Stevens MGV, Correy GJ, Diolaiti ME, Smith DH, Ashworth A, Stroud RM, Kelly MJS, Bondy-Denomy J, Fraser JS
• Extensive exploration of structure activity relationships for the SARS-CoV-2 macrodomain from shape-based fragment merging and active learning.
  bioRxiv : the preprint server for biology 2024 Correy GJ, Rachman M, Togo T, Gahbauer S, Doruk YU, Stevens M, Jaishankar P, Kelley B, Goldman B, Schmidt M, Kramer T, Ashworth A, Riley P, Shoichet BK, Renslo AR, Walters WP, Fraser JS
• A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
  Cancer research communications 2024 Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P,…
• De novo design of drug-binding proteins with predictable binding energy and specificity.
  Science (New York, N.Y.) 2024 Lu L, Gou X, Tan SK, Mann SI, Yang H, Zhong X, Gazgalis D, Valdiviezo J, Jo H, Wu Y, Diolaiti ME, Ashworth A, Polizzi NF, DeGrado WF
• A roadmap to establishing global oncology as a priority initiative within a National Cancer Institute-designated cancer center.
  Journal of the National Cancer Institute 2024 Van Loon K, Breithaupt L, Ng D, DeBoer RJ, Buckle GC, Bialous S, Hiatt RA, Volberding P, Hermiston ML, Ashworth A
• Large tandem duplications in cancer result from transcription and DNA replication collisions.
  medRxiv : the preprint server for health sciences 2024 Yang Y, Badura ML, O'Leary PC, Delavan HM, Robinson TM, Egusa EA, Zhong X, Swinderman JT, Li H, Zhang M, Kim M, Ashworth A, Feng FY, Chou J, Yang L
• De novo design of drug-binding proteins with predictable binding energy and specificity.
  bioRxiv : the preprint server for biology 2023 Lu L, Gou X, Tan SK, Mann SI, Yang H, Zhong X, Gazgalis D, Valdiviezo J, Jo H, Wu Y, Diolaiti ME, Ashworth A, Polizzi NF, DeGrado WF
• Cancer Research in 2030: A unique strategic planning process at a comprehensive cancer center.
  Preventive oncology & epidemiology 2023 Bank EM, Small EJ, Ashworth A, Hiatt RA
• A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivo.
  PLoS pathogens 2023 Taha TY, Suryawanshi RK, Chen IP, Correy GJ, McCavitt-Malvido M, O'Leary PC, Jogalekar MP, Diolaiti ME, Kimmerly GR, Tsou CL, Gascon R, Montano M, Martinez-Sobrido L, Krogan NJ, Ashworth A, Fraser JS,…
• NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy.
  bioRxiv : the preprint server for biology 2023 Choudhury A, Cady MA, Lucas CG, Najem H, Phillips JJ, Palikuqi B, Zakimi N, Joseph T, Birrueta JO, Chen WC, Bush NAO, Hervey-Jumper SL, Klein OD, Toedebusch CM, Horbinski CM, Magill ST, Bhaduri A, …
• A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis in vivo.
  bioRxiv : the preprint server for biology 2023 Taha TY, Suryawanshi RK, Chen IP, Correy GJ, O'Leary PC, Jogalekar MP, McCavitt-Malvido M, Diolaiti ME, Kimmerly GR, Tsou CL, Martinez-Sobrido L, Krogan NJ, Ashworth A, Fraser JS, Ott M
• Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology.
  NPJ breast cancer 2023 Mandair D, Reis-Filho JS, Ashworth A
• Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
  Cancer research 2023 Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, …
• TEAD Proteins Associate With DNA Repair Proteins to Facilitate Cellular Recovery From DNA Damage.
  Molecular & cellular proteomics : MCP 2023 Calses PC, Pham VC, Guarnaccia AD, Choi M, Verschueren E, Bakker ST, Pham TH, Hinkle T, Liu C, Chang MT, Kljavin N, Bakalarski C, Haley B, Zou J, Yan C, Song X, Lin X, Rowntree R, Ashworth A, Dey A, …
• Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2.
  Proceedings of the National Academy of Sciences of the United States of America 2023 Gahbauer S, Correy GJ, Schuller M, Ferla MP, Doruk YU, Rachman M, Wu T, Diolaiti M, Wang S, Neitz RJ, Fearon D, Radchenko DS, Moroz YS, Irwin JJ, Renslo AR, Taylor JC, Gestwicki JE, von Delft F, …
• PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors.
  Molecular cancer therapeutics 2022 Thomas A, Fontaine SD, Diolaiti ME, Desai P, Kumar R, Takahashi N, Sciuto L, Nichols S, Ashworth A, Feng FY, Ashley GW, Nguyen M, Pommier Y, Santi DV
• Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2.
  Cancer research 2022 O'Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, Shenoy T, Kale N, Carnevale J, Stevenson E, Quigley DA, Chou J, Feng FY, Swaney DL, Krogan NJ, Kim M, Diolaiti ME, Ashworth A
• The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
  Cancer research 2022 Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, …
• RASA2 ablation in T cells boosts antigen sensitivity and long-term function.
  Nature 2022 Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, …
• Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 Macrodomain of SARS-CoV-2.
  bioRxiv : the preprint server for biology 2022 Gahbauer S, Correy GJ, Schuller M, Ferla MP, Doruk YU, Rachman M, Wu T, Diolaiti M, Wang S, Neitz RJ, Fearon D, Radchenko D, Moroz Y, Irwin JJ, Renslo AR, Taylor JC, Gestwicki JE, von Delft F, …
• A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor.
  Molecular cancer therapeutics 2022 Chen H, Diolaiti ME, O'Leary PC, Rojc A, Krogan NJ, Kim M, Ashworth A
• Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence.
  Cancer cell 2022 Belk JA, Yao W, Ly N, Freitas KA, Chen YT, Shi Q, Valencia AM, Shifrut E, Kale N, Yost KE, Duffy CV, Daniel B, Hwee MA, Miao Z, Ashworth A, Mackall CL, Marson A, Carnevale J, Vardhana SA, Satpathy AT
• The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and x-ray diffraction at room temperature.
  Science advances 2022 Correy GJ, Kneller DW, Phillips G, Pant S, Russi S, Cohen AE, Meigs G, Holton JM, Gahbauer S, Thompson MC, Ashworth A, Coates L, Kovalevsky A, Meilleur F, Fraser JS
• Validation of Anticorrelated TGFβ Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Guix I, Liu Q, Pujana MA, Ha P, Piulats J, Linares I, Guedea F, Mao JH, Lazar A, Chapman J, Yom SS, Ashworth A, Barcellos-Hoff MH
• From Cancer Epidemiology to Policy and Practice: the Role of a Comprehensive Cancer Center.
  Current epidemiology reports 2022 Hiatt RA, Sibley A, Venkatesh B, Cheng J, Dixit N, Fox R, Ling P, Nguyen T, Oh D, Palmer NR, Pasick RJ, Potter MB, Somsouk M, Vargas RA, Vijayaraghavan M, Ashworth A
• Hypoxia Is a Dominant Remodeler of the Effector T Cell Surface Proteome Relative to Activation and Regulatory T Cell Suppression.
  Molecular & cellular proteomics : MCP 2022 Byrnes JR, Weeks AM, Shifrut E, Carnevale J, Kirkemo L, Ashworth A, Marson A, Wells JA
• The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and X-ray diffraction at room temperature.
  bioRxiv : the preprint server for biology 2022 Correy GJ, Kneller DW, Phillips G, Pant S, Russi S, Cohen AE, Meigs G, Holton JM, Gahbauer S, Thompson MC, Ashworth A, Coates L, Kovalevsky A, Meilleur F, Fraser JS
• A protein interaction landscape of breast cancer.
  Science (New York, N.Y.) 2021 Kim M, Park J, Bouhaddou M, Kim K, Rojc A, Modak M, Soucheray M, McGregor MJ, O'Leary P, Wolf D, Stevenson E, Foo TK, Mitchell D, Herrington KA, Muñoz DP, Tutuncuoglu B, Chen KH, Zheng F, Kreisberg JF…
• Incidence of candidaemia in prolonged venovenous extracorporeal membrane oxygenation.
  The Journal of hospital infection 2021 Monk EJM, Rautemaa-Richardson R, Felton T, Montalti A, Parkes M, Templeton R, Ashworth A, Garcia M, Barker J, Thomas S
• ADP-ribosyltransferases, an update on function and nomenclature.
  The FEBS journal 2021 Lüscher B, Ahel I, Altmeyer M, Ashworth A, Bai P, Chang P, Cohen M, Corda D, Dantzer F, Daugherty MD, Dawson TM, Dawson VL, Deindl S, Fehr AR, Feijs KLH, Filippov DV, Gagné JP, Grimaldi G, Guettler S,…
• An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.
  Nature communications 2021 Das R, Sjöström M, Shrestha R, Yogodzinski C, Egusa EA, Chesner LN, Chen WS, Chou J, Dang DK, Swinderman JT, Ge A, Hua JT, Kabir S, Quigley DA, Small EJ, Ashworth A, Feng FY, Gilbert LA
• ATR Inhibitors and Paclitaxel in Melanoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Ashworth A
• Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking.
  Science advances 2021 Schuller M, Correy GJ, Gahbauer S, Fearon D, Wu T, Díaz RE, Young ID, Carvalho Martins L, Smith DH, Schulze-Gahmen U, Owens TW, Deshpande I, Merz GE, Thwin AC, Biel JT, Peters JK, Moritz M, Herrera N,…
• Common Susceptibility Loci for Male Breast Cancer.
  Journal of the National Cancer Institute 2021 Maguire S, Perraki E, Tomczyk K, Jones ME, Fletcher O, Pugh M, Winter T, Thompson K, Cooke R, kConFab Consortium, Trainer A, James P, Bojesen S, Flyger H, Nevanlinna H, Mattson J, Friedman E, Laitman …
• A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models.
  Cancer research 2020 Fontaine SD, Ashley GW, Houghton PJ, Kurmasheva RT, Diolaiti M, Ashworth A, Peer CJ, Nguyen R, Figg WD, Beckford-Vera DR, Santi DV
• Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic Screening and Computational Docking.
  bioRxiv : the preprint server for biology 2020 Schuller M, Correy GJ, Gahbauer S, Fearon D, Wu T, Díaz RE, Young ID, Martins LC, Smith DH, Schulze-Gahmen U, Owens TW, Deshpande I, Merz GE, Thwin AC, Biel JT, Peters JK, Moritz M, Herrera N, …
• Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA.
  Nature communications 2020 Guler GD, Ning Y, Ku CJ, Phillips T, McCarthy E, Ellison CK, Bergamaschi A, Collin F, Lloyd P, Scott A, Antoine M, Wang W, Chau K, Ashworth A, Quake SR, Levy S
• Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer.
  Gastroenterology 2020 Dreyer SB, Upstill-Goddard R, Paulus-Hock V, Paris C, Lampraki EM, Dray E, Serrels B, Caligiuri G, Rebus S, Plenker D, Galluzzo Z, Brunton H, Cunningham R, Tesson M, Nourse C, Bailey UM, Jones M, …
• Autoantibody Landscape in Patients with Advanced Prostate Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M…
• Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24 + CD29/CD49fhi in mice.
  Breast cancer research and treatment 2020 Dall GV, Vieusseux J, Seyed-Razavi Y, Godde N, Ludford-Menting M, Russell SM, Ashworth A, Anderson RL, Risbridger GP, Shackleton M, Britt KL
• The DNA methylation landscape of advanced prostate cancer.
  Nature genetics 2020 Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, …
• Klotho and the Treatment of Human Malignancies.
  Cancers 2020 Sachdeva A, Gouge J, Kontovounisios C, Nikolaou S, Ashworth A, Lim K, Chong I
• HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer.
  Cell reports 2020 Brunton H, Caligiuri G, Cunningham R, Upstill-Goddard R, Bailey UM, Garner IM, Nourse C, Dreyer S, Jones M, Moran-Jones K, Wright DW, Paulus-Hock V, Nixon C, Thomson G, Jamieson NB, McGregor GA, Evers…
• A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
  Nature 2020 Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Hüttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, …
• A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing.
  bioRxiv : the preprint server for biology 2020 Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O'Meara MJ, Guo JZ, Swaney DL, Tummino TA, Huettenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, …
• Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking.
  Nature communications 2020 Cresswell GD, Nichol D, Spiteri I, Tari H, Zapata L, Heide T, Maley CC, Magnani L, Schiavon G, Ashworth A, Barry P, Sottoriva A
• An integrated molecular profile of endometrioid ovarian cancer.
  Gynecologic oncology 2020 Pierson WE, Peters PN, Chang MT, Chen LM, Quigley DA, Ashworth A, Chapman JS
• Venoarterial extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock-A six-year service evaluation.
  Artificial organs 2020 Charlesworth M, Garcia M, Head L, Barker JM, Ashworth AD, Barnard JB, Feddy L, Venkateswaran RV
• Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
  Cancer discovery 2020 Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A
• Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.
  Breast cancer research : BCR 2020 Bodicoat DH, Schoemaker MJ, Jones ME, McFadden E, Griffin J, Ashworth A, Swerdlow AJ
• Microbial contamination of heater cooler units used in extracorporeal membrane oxygenation is not aerosolized into the environment: A single-center experience.
  Infection control and hospital epidemiology 2020 Thomas S, Stevenson D, Otu AA, Vergidis P, Barker J, Ashworth A, Exton P, Richardson M, George R, Moore G
• A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.
  Nature communications 2020 Escala-Garcia M, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Ashworth A, Auer PL, Auvinen P, Beckmann MW, Beesley J, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Blot W, Bogdanova NV, Bojesen…
• Synthetic lethality as an engine for cancer drug target discovery.
  Nature reviews. Drug discovery 2019 Huang A, Garraway LA, Ashworth A, Weber B
• Klotho: A Major Shareholder in Vascular Aging Enterprises.
  International journal of molecular sciences 2019 Lim K, Halim A, Lu TS, Ashworth A, Chong I
• Strategies for the prevention of peri-operative transoesophageal echocardiography-related complications.
  Anaesthesia 2019 Ashworth AD, Greenhalgh DL
• DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley …
• Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.
  Journal of medicinal chemistry 2019 Velagapudi UK, Langelier MF, Delgado-Martin C, Diolaiti ME, Bakker S, Ashworth A, Patel BA, Shao X, Pascal JM, Talele TT
• A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers.
  Nature communications 2019 Mondal G, Stevers M, Goode B, Ashworth A, Solomon DA
• PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
  The Journal of clinical investigation 2019 Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Rouanne M, Marlow R, Bajrami I, Cardeñosa ML, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, …
• A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.
  Scientific reports 2019 Menon M, Elliott R, Bowers L, Balan N, Rafiq R, Costa-Cabral S, Munkonge F, Trinidade I, Porter R, Campbell AD, Johnson ER, Esdar C, Buchstaller HP, Leuthner B, Rohdich F, Schneider R, Sansom O, …
• Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
  British journal of cancer 2018 Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ
• Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function.
  Cell 2018 Shifrut E, Carnevale J, Tobin V, Roth TL, Woo JM, Bui CT, Li PJ, Diolaiti ME, Ashworth A, Marson A
• Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
  PloS one 2018 Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A
• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
  Cell 2018 Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, …
• Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
  British journal of cancer 2018 Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ
• Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
  Nature reviews. Clinical oncology 2018 Ashworth A, Lord CJ
• Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
  Scientific reports 2018 Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL,…
• Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
  JAMA dermatology 2018 Danilenko M, Stamp E, Stocken DD, Husain A, Zangarini M, Cranston A, Stones R, Sinclair N, Hodgson K, Bowett SA, Roblin D, Traversa S, Plummer R, Veal G, Langtry JAA, Ashworth A, Burn J, Rajan N
• Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
  Cell 2018 Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, …
• Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
  Scientific reports 2018 Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL,…
• Reprogramming human T cell function and specificity with non-viral genome targeting.
  Nature 2018 Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, Chen JW, Schickel JN, Pellerin L, Carmody D, Alkorta…
• Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets.
  Nature communications 2018 Krastev DB, Pettitt SJ, Campbell J, Song F, Tanos BE, Stoynov SS, Ashworth A, Lord CJ
• Reply to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
  British journal of cancer 2018 Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ
• Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
  Nature communications 2018 Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, …
• Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
  Nature medicine 2018 Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, …
• Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.
  Nature communications 2018 Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R…
• E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.
  Cancer discovery 2018 Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, …
• Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study.
  International journal of cancer 2018 Wright LB, Schoemaker MJ, Jones ME, Ashworth A, Swerdlow AJ
• DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade.
  The Journal of clinical investigation 2018 Touat M, Sourisseau T, Dorvault N, Chabanon RM, Garrido M, Morel D, Krastev DB, Bigot L, Adam J, Frankum JR, Durand S, Pontoizeau C, Souquère S, Kuo MS, Sauvaigo S, Mardakheh F, Sarasin A, Olaussen KA…
• Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry.
  Cell reports 2018 Gonzalez VD, Samusik N, Chen TJ, Savig ES, Aghaeepour N, Quigley DA, Huang YW, Giangarrà V, Borowsky AD, Hubbard NE, Chen SY, Han G, Ashworth A, Kipps TJ, Berek JS, Nolan GP, Fantl WJ
• Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study.
  British journal of cancer 2018 Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ
• The San Francisco Cancer Initiative: A Community Effort To Reduce The Population Burden Of Cancer.
  Health affairs (Project Hope) 2018 Hiatt RA, Sibley A, Fejerman L, Glantz S, Nguyen T, Pasick R, Palmer N, Perkins A, Potter MB, Somsouk M, Vargas RA, van 't Veer LJ, Ashworth A
• Smoking and risk of breast cancer in the Generations Study cohort.
  Breast cancer research : BCR 2017 Jones ME, Schoemaker MJ, Wright LB, Ashworth A, Swerdlow AJ
• Future cancer research priorities in the USA: a Lancet Oncology Commission.
  The Lancet. Oncology 2017 Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, …
• ATR Is a Therapeutic Target in Synovial Sarcoma.
  Cancer research 2017 Jones SE, Fleuren EDG, Frankum J, Konde A, Williamson CT, Krastev DB, Pemberton HN, Campbell J, Gulati A, Elliott R, Menon M, Selfe JL, Brough R, Pettitt SJ, Niedzwiedz W, van der Graaf WTA, Shipley J…
• Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.
  Gut 2017 Chong IY, Aronson L, Bryant H, Gulati A, Campbell J, Elliott R, Pettitt S, Wilkerson P, Lambros MB, Reis-Filho JS, Ramessur A, Davidson M, Chau I, Cunningham D, Ashworth A, Lord CJ
• Structural basis for recruitment of BRCA2 by PALB2.
  EMBO reports 2017 Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH
• Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.
  Molecular cancer therapeutics 2017 Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ
• Family history and risk of breast cancer: an analysis accounting for family structure.
  Breast cancer research and treatment 2017 Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ
• Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
  British journal of cancer 2017 Nikkilä J, Kumar R, Campbell J, Brandsma I, Pemberton HN, Wallberg F, Nagy K, Scheer I, Vertessy BG, Serebrenik AA, Monni V, Harris RS, Pettitt SJ, Ashworth A, Lord CJ
• Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
  Cancer discovery 2017 Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, …
• Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
  PloS one 2017 Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A
• PARP inhibitors: Synthetic lethality in the clinic.
  Science (New York, N.Y.) 2017 Lord CJ, Ashworth A
• Marked for death: targeting epigenetic changes in cancer.
  Nature reviews. Drug discovery 2017 Pfister SX, Ashworth A
• Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells.
  Scientific data 2017 Pettitt SJ, Krastev DB, Pemberton HN, Fontebasso Y, Frankum J, Rehman FL, Brough R, Song F, Bajrami I, Rafiq R, Wallberg F, Kozarewa I, Fenwick K, Armisen-Garrido J, Swain A, Gulati A, Campbell J, …
• Childhood body size and pubertal timing in relation to adult mammographic density phenotype.
  Breast cancer research : BCR 2017 Schoemaker MJ, Jones ME, Allen S, Hoare J, Ashworth A, Dowsett M, Swerdlow AJ
• ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.
  Nature communications 2016 Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, Badham N, Rafiq R, Brough R, Gulati A, Ryan CJ, Francis J, Vermulen PB, Reynolds AR, Reaper PM, Pollard JR, Ashworth A, Lord CJ
• PARP inhibitor combination therapy.
  Critical reviews in oncology/hematology 2016 Dréan A, Lord CJ, Ashworth A
• PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
  Journal of medical genetics 2016 Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, Foulkes WD, Dennis J, Michailidou K, van Rensburg EJ, Heikkinen T, Nevanlinna H, Hopper JL, Dörk T, Claes KB, Reis-Filho J, Teo ZL…
• Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
  British journal of cancer 2016 Jones ME, Schoemaker MJ, Wright L, McFadden E, Griffin J, Thomas D, Hemming J, Wright K, Ashworth A, Swerdlow AJ
• Psychological stress, adverse life events and breast cancer incidence: a cohort investigation in 106,000 women in the United Kingdom.
  Breast cancer research : BCR 2016 Schoemaker MJ, Jones ME, Wright LB, Griffin J, McFadden E, Ashworth A, Swerdlow AJ
• Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
  Molecular cancer therapeutics 2016 Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, …
• DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
  The oncologist 2016 Dhawan M, Ryan CJ, Ashworth A
• Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.
  The Journal of biological chemistry 2016 Beck D, Zobel J, Barber R, Evans S, Lezina L, Allchin RL, Blades M, Elliott R, Lord CJ, Ashworth A, Porter AC, Wagner SD
• Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells.
  The Journal of pathology 2016 Rajan N, Andersson MK, Sinclair N, Fehr A, Hodgson K, Lord CJ, Kazakov DV, Vanecek T, Ashworth A, Stenman G
• Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
  PloS one 2016 Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A
• Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
  Cancer research 2016 Johnson N, De Ieso P, Migliorini G, Orr N, Broderick P, Catovsky D, Matakidou A, Eisen T, Goldsmith C, Dudbridge F, Peto J, Dos-Santos-Silva I, Ashworth A, Ross G, Houlston RS, Fletcher O
• Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.
  Cell reports 2016 Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller R, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, Quigley DA, Tym J, Al-Lazikani …
• CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
  PloS one 2016 Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A
• BRCAness revisited.
  Nature reviews. Cancer 2016 Lord CJ, Ashworth A
• Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.
  Nature medicine 2015 Esposito MT, Zhao L, Fung TK, Rane JK, Wilson A, Martin N, Gil J, Leung AY, Ashworth A, So CW
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
  The New England journal of medicine 2015 Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, …
• Exome Sequencing of an Adult Pituitary Atypical Teratoid Rhabdoid Tumor.
  Frontiers in oncology 2015 Biswas S, Wood M, Joshi A, Bown N, Strain L, Martinsson T, Campbell J, Ashworth A, Swain A
• Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization.
  Journal of the National Cancer Institute 2015 Zhang B, Shu XO, Delahanty RJ, Zeng C, Michailidou K, Bolla MK, Wang Q, Dennis J, Wen W, Long J, Li C, Dunning AM, Chang-Claude J, Shah M, Perkins BJ, Czene K, Darabi H, Eriksson M, Bojesen SE, …
• Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
  Molecular cancer therapeutics 2015 Kwon YJ, Petrie K, Leibovitch BA, Zeng L, Mezei M, Howell L, Gil V, Christova R, Bansal N, Yang S, Sharma R, Ariztia EV, Frankum J, Brough R, Sbirkov Y, Ashworth A, Lord CJ, Zelent A, Farias E, Zhou …
• The cancer cell map initiative: defining the hallmark networks of cancer.
  Molecular cell 2015 Krogan NJ, Lippman S, Agard DA, Ashworth A, Ideker T
• Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Carnevale J, Ashworth A
• Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Breast Cancer.
  Cancer research 2015 Lemnrau A, Brook MN, Fletcher O, Coulson P, Tomczyk K, Jones M, Ashworth A, Swerdlow A, Orr N, Garcia-Closas M
• Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
  Oncotarget 2015 Frankum J, Moudry P, Brough R, Hodny Z, Ashworth A, Bartek J, Lord CJ
• Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.
  Oncotarget 2015 Conti A, Majorini MT, Elliott R, Ashworth A, Lord CJ, Cancelliere C, Bardelli A, Seneci P, Walczak H, Delia D, Lecis D
• No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
  Gynecologic oncology 2015 Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modif, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, …
• Prediction of breast cancer risk based on profiling with common genetic variants.
  Journal of the National Cancer Institute 2015 Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, Wang Q, Dennis J, Dunning AM, Shah M, Luben R, Brown J, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Czene K, Darabi H, …
• Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours.
  The Journal of pathology 2015 Francis JC, Melchor L, Campbell J, Kendrick H, Wei W, Armisen-Garrido J, Assiotis I, Chen L, Kozarewa I, Fenwick K, Swain A, Smalley MJ, Lord CJ, Ashworth A
• Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.
  Cancer discovery 2015 Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, Gillett C, Pinder S, Vanoli F, Jasin M, Mayrhofer M, Isaksson A, Cheang MC, Mirza H, Frankum J, Lord CJ, Ashworth A, Vinayak S, Ford JM, …
• Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways.
  Molecular cancer therapeutics 2015 Aarts M, Bajrami I, Herrera-Abreu MT, Elliott R, Brough R, Ashworth A, Lord CJ, Turner NC
• Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2.
  Human molecular genetics 2015 Orr N, Dudbridge F, Dryden N, Maguire S, Novo D, Perrakis E, Johnson N, Ghoussaini M, Hopper JL, Southey MC, Apicella C, Stone J, Schmidt MK, Broeks A, Van't Veer LJ, Hogervorst FB, Fasching PA, …
• Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer.
  Carcinogenesis 2015 Kabisch M, Lorenzo Bermejo J, Dünnebier T, Ying S, Michailidou K, Bolla MK, Wang Q, Dennis J, Shah M, Perkins BJ, Czene K, Darabi H, Eriksson M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, …
• The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling.
  Oncotarget 2014 Rajan N, Elliott RJ, Smith A, Sinclair N, Swift S, Lord CJ, Ashworth A
• MicroRNA related polymorphisms and breast cancer risk.
  PloS one 2014 Khan S, Greco D, Michailidou K, Milne RL, Muranen TA, Heikkinen T, Aaltonen K, Dennis J, Bolla MK, Liu J, Hall P, Irwanto A, Humphreys K, Li J, Czene K, Chang-Claude J, Hein R, Rudolph A, Seibold P, …
• Temporal stability and determinants of white blood cell DNA methylation in the breakthrough generations study.
  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2014 Flanagan JM, Brook MN, Orr N, Tomczyk K, Coulson P, Fletcher O, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow A, Brown R, Garcia-Closas M
• Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
  Annual review of medicine 2014 Lord CJ, Tutt AN, Ashworth A
• Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.
  Nature communications 2014 Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R…
• DAISY: picking synthetic lethals from cancer genomes.
  Cancer cell 2014 Ryan CJ, Lord CJ, Ashworth A
• Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.
  Cancer research 2014 Gao S, Bajrami I, Verrill C, Kigozi A, Ouaret D, Aleksic T, Asher R, Han C, Allen P, Bailey D, Feller S, Kashima T, Athanasou N, Blay JY, Schmitz S, Machiels JP, Upile N, Jones TM, Thalmann G, Ashraf …
• Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk.
  Human molecular genetics 2014 Lin WY, Camp NJ, Ghoussaini M, Beesley J, Michailidou K, Hopper JL, Apicella C, Southey MC, Stone J, Schmidt MK, Broeks A, Van't Veer LJ, Th Rutgers EJ, Muir K, Lophatananon A, Stewart-Brown S, …
• Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C.
  Genome research 2014 Dryden NH, Broome LR, Dudbridge F, Johnson N, Orr N, Schoenfelder S, Nagano T, Andrews S, Wingett S, Kozarewa I, Assiotis I, Fenwick K, Maguire SL, Campbell J, Natrajan R, Lambros M, Perrakis E, …
• Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium.
  Human molecular genetics 2014 Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menéndez-Rodríguez P, Hardisson D, Mendiola M, González-Neira A, Pita G, Alonso MR, Dennis J, Wang Q, Bolla MK, Swerdlow A, Ashworth A,…
• Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade.
  Human molecular genetics 2014 Purrington KS, Slettedahl S, Bolla MK, Michailidou K, Czene K, Nevanlinna H, Bojesen SE, Andrulis IL, Cox A, Hall P, Carpenter J, Yannoukakos D, Haiman CA, Fasching PA, Mannermaa A, Winqvist R, …
• Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study.
  Breast cancer research : BCR 2014 Johnson N, Dudbridge F, Orr N, Gibson L, Jones ME, Schoemaker MJ, Folkerd EJ, Haynes BP, Hopper JL, Southey MC, Dite GS, Apicella C, Schmidt MK, Broeks A, Van't Veer LJ, Atsma F, Muir K, Lophatananon …
• Genetic predisposition to in situ and invasive lobular carcinoma of the breast.
  PLoS genetics 2014 Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, Fletcher O, Pinder S, Hanby A, Kohut K, Gorman P, Caneppele M, Peto J, Dos Santos Silva I, Johnson N, Swann R, Dwek M, Perkins KA, …
• An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor.
  Cancer discovery 2014 Murugaesu N, Iravani M, van Weverwijk A, Ivetic A, Johnson DA, Antonopoulos A, Fearns A, Jamal-Hanjani M, Sims D, Fenwick K, Mitsopoulos C, Gao Q, Orr N, Zvelebil M, Haslam SM, Dell A, Yarwood H, Lord…
• Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.
  The Journal of pathology 2014 Natrajan R, Wilkerson PM, Marchiò C, Piscuoglio S, Ng CK, Wai P, Lambros MB, Samartzis EP, Dedes KJ, Frankum J, Bajrami I, Kopec A, Mackay A, A'hern R, Fenwick K, Kozarewa I, Hakas J, Mitsopoulos C, …
• Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.
  American journal of human genetics 2013 Meyer KB, O'Reilly M, Michailidou K, Carlebur S, Edwards SL, French JD, Prathalingham R, Dennis J, Bolla MK, Wang Q, de Santiago I, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Schmidt MK, Broeks A…
• Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
  Cancer research 2013 Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A
• Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.
  Endocrine-related cancer 2013 Rudolph A, Hein R, Lindström S, Beckmann L, Behrens S, Liu J, Aschard H, Bolla MK, Wang J, Truong T, Cordina-Duverger E, Menegaux F, Brüning T, Harth V, GENICA Network, Severi G, Baglietto L, Southey …
• The genomic landscape of oesophagogastric junctional adenocarcinoma.
  The Journal of pathology 2013 Chong IY, Cunningham D, Barber LJ, Campbell J, Chen L, Kozarewa I, Fenwick K, Assiotis I, Guettler S, Garcia-Murillas I, Awan S, Lambros M, Starling N, Wotherspoon A, Stamp G, Gonzalez-de-Castro D, …
• Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
  Nature medicine 2013 Lord CJ, Ashworth A
• Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, …
• Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase.
  Molecular cancer therapeutics 2013 Mereniuk TR, El Gendy MA, Mendes-Pereira AM, Lord CJ, Ghosh S, Foley E, Ashworth A, Weinfeld M
• BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A
• Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
  Cancer discovery 2013 Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A, Turner NC
• Changes in estradiol and testosterone levels in postmenopausal women after changes in body mass index.
  The Journal of clinical endocrinology and metabolism 2013 Jones ME, Schoemaker M, Rae M, Folkerd EJ, Dowsett M, Ashworth A, Swerdlow AJ
• Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.
  Cancer discovery 2013 Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S, Bax DA, Carvalho D, Taylor KR, Vinci M, Bajrami I, McGonnell IM, Lord CJ, Reis RM, Hargrave D, Ashworth A, Workman P, Jones C
• Noninvasive detection of HER2 amplification with plasma DNA digital PCR.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, Smith IE, Ashworth A, Turner NC
• A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.
  PloS one 2013 Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell J, Lord CJ, Ashworth A
• Identification of miRNA modulators to PARP inhibitor response.
  DNA repair 2013 Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A
• Genome-wide association studies identify four ER negative-specific breast cancer risk loci.
  Nature genetics 2013 Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E, Feigelson HS, Le Marchand L, Buring JE, Eccles D, Miron P, Fasching PA, Brauch H, Chang-Claude J,…
• Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
  Nature genetics 2013 Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, Karevan R, Woods N, Johnston RL, …
• Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
  The Journal of pathology 2013 Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A
• Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
  Nature 2012 Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, Rodrigues DN, Renwick A, Seal S, Ramsay E, Duarte Sdel V, Rivas MA, Warren-Perry M, Zachariou A, Campion-Flora A, Hanks S, Murray A, Ansari…
• Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.
  Nature reviews. Drug discovery 2012 Riffell JL, Lord CJ, Ashworth A
• The promise of combining inhibition of PI3K and PARP as cancer therapy.
  Cancer discovery 2012 Rehman FL, Lord CJ, Ashworth A
• NLK is a novel therapeutic target for PTEN deficient tumour cells.
  PloS one 2012 Mendes-Pereira AM, Lord CJ, Ashworth A
• Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk.
  Nature genetics 2012 Orr N, Lemnrau A, Cooke R, Fletcher O, Tomczyk K, Jones M, Johnson N, Lord CJ, Mitsopoulos C, Zvelebil M, McDade SS, Buck G, Blancher C, KConFab Consortium, Trainer AH, James PA, Bojesen SE, Bokmand S…
• Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
  EMBO molecular medicine 2012 Bajrami I, Kigozi A, Van Weverwijk A, Brough R, Frankum J, Lord CJ, Ashworth A
• Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
  Breast cancer research and treatment 2012 Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ
• Genomic characterisation of acral melanoma cell lines.
  Pigment cell & melanoma research 2012 Furney SJ, Turajlic S, Fenwick K, Lambros MB, MacKay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H, Marais R
• Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
  Stem cells (Dayton, Ohio) 2012 Stratford AL, Reipas K, Hu K, Fotovati A, Brough R, Frankum J, Takhar M, Watson P, Ashworth A, Lord CJ, Lasham A, Print CG, Dunn SE
• Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation.
  Nucleic acids research 2012 McDade SS, Henry AE, Pivato GP, Kozarewa I, Mitsopoulos C, Fenwick K, Assiotis I, Hakas J, Zvelebil M, Orr N, Lord CJ, Patel D, Ashworth A, McCance DJ
• Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.
  Blood 2012 Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, Kozarewa I, Gonzalez D, Lord CJ, Ashworth A, Davies FE, Morgan GJ
• Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor.
  Breast cancer research and treatment 2012 Iorns E, Ward TM, Dean S, Jegg A, Thomas D, Murugaesu N, Sims D, Mitsopoulos C, Fenwick K, Kozarewa I, Naceur-Lombarelli C, Zvelebil M, Isacke CM, Lord CJ, Ashworth A, Hnatyszyn HJ, Pegram M, Lippman …
• Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
  Cancer discovery 2012 Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, Toniatti C, Ashworth A, Turner NC
• Body mass index, exercise, and other lifestyle factors in relation to age at natural menopause: analyses from the breakthrough generations study.
  American journal of epidemiology 2012 Morris DH, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ
• CYP3A variation, premenopausal estrone levels, and breast cancer risk.
  Journal of the National Cancer Institute 2012 Johnson N, Walker K, Gibson LJ, Orr N, Folkerd E, Haynes B, Palles C, Coupland B, Schoemaker M, Jones M, Broderick P, Sawyer E, Kerin M, Tomlinson IP, Zvelebil M, Chilcott-Burns S, Tomczyk K, Simpson …
• A modified method for whole exome resequencing from minimal amounts of starting DNA.
  PloS one 2012 Kozarewa I, Rosa-Rosa JM, Wardell CP, Walker BA, Fenwick K, Assiotis I, Mitsopoulos C, Zvelebil M, Morgan GJ, Ashworth A, Lord CJ, J C
• Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.
  Cancer research 2012 Brennan K, Garcia-Closas M, Orr N, Fletcher O, Jones M, Ashworth A, Swerdlow A, Thorne H, KConFab Investigators, Riboli E, Vineis P, Dorronsoro M, Clavel-Chapelon F, Panico S, Onland-Moret NC, …
• A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.
  The Journal of pathology 2012 Natrajan R, Mackay A, Lambros MB, Weigelt B, Wilkerson PM, Manie E, Grigoriadis A, A'Hern R, van der Groep P, Kozarewa I, Popova T, Mariani O, Turaljic S, Furney SJ, Marais R, Rodruigues DN, Flora AC,…
• The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.
  Nature reviews. Clinical oncology 2012 Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC
• 19p13.1 is a triple-negative-specific breast cancer susceptibility locus.
  Cancer research 2012 Stevens KN, Fredericksen Z, Vachon CM, Wang X, Margolin S, Lindblom A, Nevanlinna H, Greco D, Aittomäki K, Blomqvist C, Chang-Claude J, Vrieling A, Flesch-Janys D, Sinn HP, Wang-Gohrke S, Nickels S, …
• APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.
  The EMBO journal 2012 Brough R, Bajrami I, Vatcheva R, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A
• The DNA damage response and cancer therapy.
  Nature 2012 Lord CJ, Ashworth A
• Whole genome sequencing of matched primary and metastatic acral melanomas.
  Genome research 2011 Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, Mackay A, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Thomas M, Stamp G, Larkin J, Reis-Filho JS, Marais R
• FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma.
  Blood 2011 Ma YP, van Leeuwen FE, Cooke R, Broeks A, Enciso-Mora V, Olver B, Lloyd A, Broderick P, Russell NS, Janus C, Ashworth A, Houlston RS, Swerdlow AJ
• Familial concordance for height and its components: analyses from the Breakthrough Generations Study.
  American journal of human biology : the official journal of the Human Biology Council 2011 Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ
• Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.
  BMC medical genomics 2011 Ha KC, Lalonde E, Li L, Cavallone L, Natrajan R, Lambros MB, Mitsopoulos C, Hakas J, Kozarewa I, Fenwick K, Lord CJ, Ashworth A, Vincent-Salomon A, Basik M, Reis-Filho JS, Majewski J, Foulkes WD
• High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing.
  Genome biology 2011 Sims D, Mendes-Pereira AM, Frankum J, Burgess D, Cerone MA, Lombardelli C, Mitsopoulos C, Hakas J, Murugaesu N, Isacke CM, Fenwick K, Assiotis I, Kozarewa I, Zvelebil M, Ashworth A, Lord CJ
• Genetic variants at chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 influence the risk of breast cancer in men.
  PLoS genetics 2011 Orr N, Cooke R, Jones M, Fletcher O, Dudbridge F, Chilcott-Burns S, Tomczyk K, Broderick P, Houlston R, Ashworth A, Swerdlow A
• Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma.
  Science translational medicine 2011 Tanas MR, Sboner A, Oliveira AM, Erickson-Johnson MR, Hespelt J, Hanwright PJ, Flanagan J, Luo Y, Fenwick K, Natrajan R, Mitsopoulos C, Zvelebil M, Hoch BL, Weiss SW, Debiec-Rychter M, Sciot R, West …
• Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
  Genes, chromosomes & cancer 2011 Williams RD, Al-Saadi R, Natrajan R, Mackay A, Chagtai T, Little S, Hing SN, Fenwick K, Ashworth A, Grundy P, Anderson JR, Dome JS, Perlman EJ, Jones C, Pritchard-Jones K
• Challenges translating breast cancer gene signatures into the clinic.
  Nature reviews. Clinical oncology 2011 Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS
• Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium.
  Human molecular genetics 2011 Figueroa JD, Garcia-Closas M, Humphreys M, Platte R, Hopper JL, Southey MC, Apicella C, Hammet F, Schmidt MK, Broeks A, Tollenaar RA, Van't Veer LJ, Fasching PA, Beckmann MW, Ekici AB, Strick R, Peto …
• Germline mutations in RAD51D confer susceptibility to ovarian cancer.
  Nature genetics 2011 Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson …
• Functional viability profiles of breast cancer.
  Cancer discovery 2011 Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, …
• Therapeutic potential of PARP inhibitors for metastatic breast cancer.
  Expert review of anticancer therapy 2011 Irshad S, Ashworth A, Tutt A
• An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence.
  BMC genomics 2011 Rovillain E, Mansfield L, Lord CJ, Ashworth A, Jat PS
• Functional characterization of EMSY gene amplification in human cancers.
  The Journal of pathology 2011 Wilkerson PM, Dedes KJ, Wetterskog D, Mackay A, Lambros MB, Mansour M, Frankum J, Lord CJ, Natrajan R, Ashworth A, Reis-Filho JS
• Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer.
  PloS one 2011 Barber LJ, Rosa Rosa JM, Kozarewa I, Fenwick K, Assiotis I, Mitsopoulos C, Sims D, Hakas J, Zvelebil M, Lord CJ, Ashworth A
• FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC, Natrajan R, Reynolds AR, Reis-Filho JS, Ashworth A, Turner NC
• Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression.
  The Journal of pathology 2011 Rajan N, Burn J, Langtry J, Sieber-Blum M, Lord CJ, Ashworth A
• High-throughput RNAi screening reveals novel regulators of telomerase.
  Cancer research 2011 Cerone MA, Burgess DJ, Naceur-Lombardelli C, Lord CJ, Ashworth A
• Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology.
  Breast cancer research and treatment 2011 Geyer FC, de Biase D, Lambros MB, Ragazzi M, Lopez-Garcia MA, Natrajan R, Mackay A, Kurelac I, Gasparre G, Ashworth A, Eusebi V, Reis-Filho JS, Tallini G
• Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
  Cell cycle (Georgetown, Tex.) 2011 Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS
• Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.
  Proceedings of the National Academy of Sciences of the United States of America 2011 Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, Kozarewa I, Mitsopoulos C, Hakas J, Zvelebil M, Lord CJ, Ashworth A
• Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.
  Nature reviews. Clinical oncology 2011 Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, Poole CJ, Weigelt B, Kaye SB, Molife LR
• Genetic interactions in cancer progression and treatment.
  Cell 2011 Ashworth A, Lord CJ, Reis-Filho JS
• Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement.
  Journal of the National Cancer Institute 2011 Mackay A, Weigelt B, Grigoriadis A, Kreike B, Natrajan R, A'Hern R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS
• Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar J, Thomas K, Natrajan R, Savage K, Fenwick K, Williams A, Jameson C, El-Bahrawy M, Gore ME, …
• Biomarkers of PARP inhibitor sensitivity.
  Breast cancer research and treatment 2011 Turner NC, Ashworth A
• Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study.
  Journal of the National Cancer Institute 2011 Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, Walker K, Zelenika D, Gut I, Heath S, Palles C, Coupland B, Broderick P, Schoemaker M, Jones M, Williamson J, Chilcott-Burns S, Tomczyk K, Simpson …
• Searching for synthetic lethality in cancer.
  Current opinion in genetics & development 2011 Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A
• Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers.
  Cancer research 2011 Martin SA, Hewish M, Sims D, Lord CJ, Ashworth A
• Emerging therapeutic targets in endometrial cancer.
  Nature reviews. Clinical oncology 2011 Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS
• Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.
  The Journal of pathology 2010 Lacroix-Triki M, Suarez PH, MacKay A, Lambros MB, Natrajan R, Savage K, Geyer FC, Weigelt B, Ashworth A, Reis-Filho JS
• A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3).
  Nature genetics 2010 Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, Hemminki K, van den Berg A, Olver B, Lloyd A, Dobbins SE, Lightfoot T, van Leeuwen FE, Försti A, Diepstra A, Broeks A, Vijayakrishnan J, …
• Synthetic lethal approaches to breast cancer therapy.
  Nature reviews. Clinical oncology 2010 Rehman FL, Lord CJ, Ashworth A
• PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
  Science translational medicine 2010 Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, Ashworth A, Reis-Filho JS
• Translating cancer research into targeted therapeutics.
  Nature 2010 de Bono JS, Ashworth A
• Therapeutic targeting of the DNA mismatch repair pathway.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Martin SA, Lord CJ, Ashworth A
• BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.
  Cell stem cell 2010 Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, Reis-Filho JS, Smalley MJ
• Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.
  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2010 Fletcher O, Johnson N, dos Santos Silva I, Orr N, Ashworth A, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MW,…
• A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, Dowsett M, Ashworth A, Turner NC
• Making the best of PARP inhibitors in ovarian cancer.
  Nature reviews. Clinical oncology 2010 Banerjee S, Kaye SB, Ashworth A
• Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis.
  PLoS genetics 2010 Francis JC, McCarthy A, Thomsen MK, Ashworth A, Swain A
• A distinct spectrum of copy number aberrations in pediatric high-grade gliomas.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Bax DA, Mackay A, Little SE, Carvalho D, Viana-Pereira M, Tamber N, Grigoriadis AE, Ashworth A, Reis RM, Ellison DW, Al-Sarraj S, Hargrave D, Jones C
• Does the prophylactic administration of N-acetylcysteine prevent acute kidney injury following cardiac surgery?
  Interactive cardiovascular and thoracic surgery 2010 Ashworth A, Webb ST
• PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.
  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010 Lambros MB, Natrajan R, Geyer FC, Lopez-Garcia MA, Dedes KJ, Savage K, Lacroix-Triki M, Jones RL, Lord CJ, Linardopoulos S, Ashworth A, Reis-Filho JS
• Using functional genetics to understand breast cancer biology.
  Cold Spring Harbor perspectives in biology 2010 Ashworth A, Bernards R
• DNA amplifications in breast cancer: genotypic-phenotypic correlations.
  Future oncology (London, England) 2010 Shiu KK, Natrajan R, Geyer FC, Ashworth A, Reis-Filho JS
• Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast.
  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010 Geyer FC, Lambros MB, Natrajan R, Mehta R, Mackay A, Savage K, Parry S, Ashworth A, Badve S, Reis-Filho JS
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB
• Biology-driven cancer drug development: back to the future.
  BMC biology 2010 Lord CJ, Ashworth A
• Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition.
  EMBO molecular medicine 2010 Sourisseau T, Maniotis D, McCarthy A, Tang C, Lord CJ, Ashworth A, Linardopoulos S
• Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas.
  The Journal of pathology 2010 Geyer FC, Weigelt B, Natrajan R, Lambros MB, de Biase D, Vatcheva R, Savage K, Mackay A, Ashworth A, Reis-Filho JS
• DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1.
  Cancer cell 2010 Martin SA, McCabe N, Mullarkey M, Cummins R, Burgess DJ, Nakabeppu Y, Oka S, Kay E, Lord CJ, Ashworth A
• FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
  Cancer research 2010 Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A
• Mismatch repair deficient colorectal cancer in the era of personalized treatment.
  Nature reviews. Clinical oncology 2010 Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A
• Breast cancer molecular profiling with single sample predictors: a retrospective analysis.
  The Lancet. Oncology 2010 Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS
• Genomic instability and the selection of treatments for cancer.
  The Journal of pathology 2010 Martin SA, Hewish M, Lord CJ, Ashworth A
• Familial breast cancer: the first linkage.
  The Lancet. Oncology 2009 Ashworth A
• Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma.
  Histopathology 2009 Geyer FC, Kushner YB, Lambros MB, Natrajan R, Mackay A, Tamber N, Fenwick K, Purnell D, Ashworth A, Walker RA, Reis-Filho JS
• Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation.
  The Journal of pathology 2009 McCarthy A, Lord CJ, Savage K, Grigoriadis A, Smith DP, Weigelt B, Reis-Filho JS, Ashworth A
• IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma.
  British journal of haematology 2009 Broderick P, Cunningham D, Vijayakrishnan J, Cooke R, Ashworth A, Swerdlow A, Houlston R
• Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.
  The Journal of pathology 2009 Marchiò C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, Tan DS, Mackay A, Fenwick K, Tamber N, Bussolati G, Ashworth A, Reis-Filho JS, Sapino A
• Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-alpha (ERalpha) in response to therapeutic radiation.
  The Journal of pathology 2009 Westbury CB, Reis-Filho JS, Dexter T, Mahler-Araujo B, Fenwick K, Iravani M, Grigoriadis A, Parry S, Robertson D, Mackay A, Ashworth A, Yarnold JR, Isacke CM
• Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2.
  EMBO molecular medicine 2009 Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord CJ, Ashworth A
• Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
  EMBO molecular medicine 2009 Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A
• An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.
  Breast cancer research and treatment 2009 Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, Jones C, Lord CJ, Vatcheva R, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Reis-Filho JS
• CRK7 modifies the MAPK pathway and influences the response to endocrine therapy.
  Carcinogenesis 2009 Iorns E, Martens-de Kemp SR, Lord CJ, Ashworth A
• Structural basis for recruitment of BRCA2 by PALB2.
  EMBO reports 2009 Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH
• Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components.
  The Journal of pathology 2009 Marchiò C, Iravani M, Natrajan R, Lambros MB, Geyer FC, Savage K, Parry S, Tamber N, Fenwick K, Mackay A, Schmitt FC, Bussolati G, Ellis I, Ashworth A, Sapino A, Reis-Filho JS
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
  The New England journal of medicine 2009 Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS
• Bringing DNA repair in tumors into focus.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Lord CJ, Ashworth A
• Pregnancy in the mature adult mouse does not alter the proportion of mammary epithelial stem/progenitor cells.
  Breast cancer research : BCR 2009 Britt KL, Kendrick H, Regan JL, Molyneux G, Magnay FA, Ashworth A, Smalley MJ
• Integrated functional, gene expression and genomic analysis for the identification of cancer targets.
  PloS one 2009 Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A, Mein CA, Natrajan R, Savage K, Tamber N, Reis-Filho JS, Turner NC, Ashworth A
• Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?
  Genes, chromosomes & cancer 2009 Natrajan R, Lambros MB, Geyer FC, Marchio C, Tan DS, Vatcheva R, Shiu KK, Hungermann D, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Buerger H, Reis-Filho JS
• Tiling path genomic profiling of grade 3 invasive ductal breast cancers.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Natrajan R, Lambros MB, Rodríguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchió C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG, Hungermann D, Mackay A, Grigoriadis A, Fenwick K, Tamber N, …
• PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D…
• A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines.
  Breast cancer research and treatment 2009 Mackay A, Tamber N, Fenwick K, Iravani M, Grigoriadis A, Dexter T, Lord CJ, Reis-Filho JS, Ashworth A
• Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.
  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009 Fletcher O, Johnson N, Dos Santos Silva I, Kilpivaara O, Aittomäki K, Blomqvist C, Nevanlinna H, Wasielewski M, Meijers-Heijerboer H, Broeks A, Schmidt MK, Van't Veer LJ, Bremer M, Dörk T, Chekmariova…
• Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization.
  The Biochemical journal 2009 Iorns E, Lord CJ, Ashworth A
• Drug resistance caused by reversion mutation.
  Cancer research 2008 Ashworth A
• Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Vuononvirta R, Sebire NJ, Dallosso AR, Reis-Filho JS, Williams RD, Mackay A, Fenwick K, Grigoriadis A, Ashworth A, Pritchard-Jones K, Brown KW, Vujanic GM, Jones C
• Can genetic testing guide treatment in breast cancer?
  European journal of cancer (Oxford, England : 1990) 2008 Tutt A, Ashworth A
• A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.
  DNA repair 2008 Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A
• Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation.
  Leukemia & lymphoma 2008 Rudenko HC, Else M, Dearden C, Brito-Babapulle V, Jones C, Dexter T, Fenwick K, Mackay A, Ashworth A, Matutes E, Gonzalez D, Catovsky D, Morgan GJ
• Targeted therapy for cancer using PARP inhibitors.
  Current opinion in pharmacology 2008 Lord CJ, Ashworth A
• ESR1 gene amplification in breast cancer: a common phenomenon?
  Nature genetics 2008 Reis-Filho JS, Drury S, Lambros MB, Marchio C, Johnson N, Natrajan R, Salter J, Levey P, Fletcher O, Peto J, Ashworth A, Dowsett M
• A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Ashworth A
• Dissecting resistance to endocrine therapy in breast cancer.
  Cell cycle (Georgetown, Tex.) 2008 Lord CJ, Iorns E, Ashworth A
• A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.
  The EMBO journal 2008 Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A
• BRCA1 and stem cells: tumour typecasting.
  Nature cell biology 2008 Smalley MJ, Reis-Filho JS, Ashworth A
• Lkb1 deficiency causes prostate neoplasia in the mouse.
  Cancer research 2008 Pearson HB, McCarthy A, Collins CM, Ashworth A, Clarke AR
• DNA repair deficiency as a therapeutic target in cancer.
  Current opinion in genetics & development 2008 Martin SA, Lord CJ, Ashworth A
• Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
  Laboratory investigation; a journal of technical methods and pathology 2008 Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS
• Association of genetic variants at 8q24 with breast cancer risk.
  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008 Fletcher O, Johnson N, Gibson L, Coupland B, Fraser A, Leonard A, dos Santos Silva I, Ashworth A, Houlston R, Peto J
• The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module.
  Molecular cell 2008 Komander D, Lord CJ, Scheel H, Swift S, Hofmann K, Ashworth A, Barford D
• Resistance to therapy caused by intragenic deletion in BRCA2.
  Nature 2008 Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A
• Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy.
  Human molecular genetics 2008 Palles C, Johnson N, Coupland B, Taylor C, Carvajal J, Holly J, Fentiman IS, Silva Idos S, Ashworth A, Peto J, Fletcher O
• Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
  Cancer cell 2008 Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A
• Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007.
  Gynecologic oncology 2007 Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, Workman P
• Pregnancy and the risk of breast cancer.
  Endocrine-related cancer 2007 Britt K, Ashworth A, Smalley M
• Dynamic expression of Erbb pathway members during early mammary gland morphogenesis.
  The Journal of investigative dermatology 2007 Wansbury O, Panchal H, James M, Parry S, Ashworth A, Howard B
• Neuregulin3 alters cell fate in the epidermis and mammary gland.
  BMC developmental biology 2007 Panchal H, Wansbury O, Parry S, Ashworth A, Howard B
• Functional analysis of Drosophila melanogaster BRCA2 in DNA repair.
  DNA repair 2007 Brough R, Wei D, Leulier S, Lord CJ, Rong YS, Ashworth A
• Mechanisms of disease: angiogenesis and the management of breast cancer.
  Nature clinical practice. Oncology 2007 Banerjee S, Dowsett M, Ashworth A, Martin LA
• Utilizing RNA interference to enhance cancer drug discovery.
  Nature reviews. Drug discovery 2007 Iorns E, Lord CJ, Turner N, Ashworth A
• Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH.
  Genes, chromosomes & cancer 2007 Natrajan R, Williams RD, Grigoriadis A, Mackay A, Fenwick K, Ashworth A, Dome JS, Grundy PE, Pritchard-Jones K, Jones C
• Effect of delays in processing blood samples on measured endogenous plasma sex hormone levels in women.
  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007 Jones ME, Folkerd EJ, Doody DA, Iqbal J, Dowsett M, Ashworth A, Swerdlow AJ
• RAD51, BRCA2 and DNA repair: a partial resolution.
  Nature structural & molecular biology 2007 Lord CJ, Ashworth A
• Analysis of PALB2/FANCN-associated breast cancer families.
  Proceedings of the National Academy of Sciences of the United States of America 2007 Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod SA, …
• Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.
  Human molecular genetics 2007 Johnson N, Fletcher O, Palles C, Rudd M, Webb E, Sellick G, dos Santos Silva I, McCormack V, Gibson L, Fraser A, Leonard A, Gilham C, Tavtigian SV, Ashworth A, Houlston R, Peto J
• Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, Fletcher CD, Schmitt FC, Ashworth A, Reis-Filho JS
• Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation.
  Laboratory investigation; a journal of technical methods and pathology 2007 Arriola E, Lambros MB, Jones C, Dexter T, Mackay A, Tan DS, Tamber N, Fenwick K, Ashworth A, Dowsett M, Reis-Filho JS
• Molecular response to aromatase inhibitor treatment in primary breast cancer.
  Breast cancer research : BCR 2007 Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M
• Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers.
  Breast cancer research : BCR 2007 Smalley MJ, Iravani M, Leao M, Grigoriadis A, Kendrick H, Dexter T, Fenwick K, Regan JL, Britt K, McDonald S, Lord CJ, Mackay A, Ashworth A
• Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland.
  The Journal of cell biology 2006 Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ
• FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, Iravani M, Fenwick K, Weber B, Hardisson D, Schmitt FC, Palacios J, Lakhani SR, …
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
  Cancer research 2006 McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A
• Targeting the double-strand DNA break repair pathway as a therapeutic strategy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Lord CJ, Garrett MD, Ashworth A
• Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk.
  Journal of the National Cancer Institute 2006 Fletcher O, Johnson N, Palles C, dos Santos Silva I, McCormack V, Whittaker J, Ashworth A, Peto J
• The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis.
  Breast cancer research : BCR 2006 Cleator SJ, Powles TJ, Dexter T, Fulford L, Mackay A, Smith IE, Valgeirsson H, Ashworth A, Dowsett M
• Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss.
  Genes, chromosomes & cancer 2006 Horsley SW, Mackay A, Iravani M, Fenwick K, Valgeirsson H, Dexter T, Ashworth A, Kearney L
• Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization.
  Laboratory investigation; a journal of technical methods and pathology 2006 Lambros MB, Simpson PT, Jones C, Natrajan R, Westbury C, Steele D, Savage K, Mackay A, Schmitt FC, Ashworth A, Reis-Filho JS
• 10th Biennial Helene Harris Memorial Trust meeting.
  Cancer research 2006 Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND
• Oncocytic change in pleomorphic adenoma: molecular evidence in support of an origin in neoplastic cells.
  Journal of clinical pathology 2006 Di Palma S, Lambros MB, Savage K, Jones C, Mackay A, Dexter T, Iravani M, Fenwick K, Ashworth A, Reis-Filho JS
• Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.
  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2006 Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A
• Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance.
  Breast cancer research and treatment 2006 Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'Connell P, Chang JC
• Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.
  Molecular cancer therapeutics 2006 Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, Hartley JA, Hochhauser D
• p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene.
  EMBO reports 2006 Arias-Lopez C, Lazaro-Trueba I, Kerr P, Lord CJ, Dexter T, Iravani M, Ashworth A, Silva A
• Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data.
  Breast cancer research : BCR 2006 Grigoriadis A, Mackay A, Reis-Filho JS, Steele D, Iseli C, Stevenson BJ, Jongeneel CV, Valgeirsson H, Fenwick K, Iravani M, Leao M, Simpson AJ, Strausberg RL, Jat PS, Ashworth A, Neville AM, O'Hare MJ
• CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells.
  Breast cancer research : BCR 2005 Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ
• Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA.
  Genomics 2005 Little SE, Vuononvirta R, Reis-Filho JS, Natrajan R, Iravani M, Fenwick K, Mackay A, Ashworth A, Pritchard-Jones K, Jones C
• Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study.
  Lancet (London, England) 2005 Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J
• BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.
  Cancer biology & therapy 2005 McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A
• Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification.
  Genes & development 2005 Howard B, Panchal H, McCarthy A, Ashworth A
• Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity.
  The Journal of pathology 2005 Reis-Filho JS, Simpson PT, Jones C, Steele D, Mackay A, Iravani M, Fenwick K, Valgeirsson H, Lambros M, Ashworth A, Palacios J, Schmitt F, Lakhani SR
• Oh what a tangled web it weaves: BRCA1 and DNA decatenation.
  Cancer cell 2005 Ashworth A
• Targeting the DNA repair defect of BRCA tumours.
  Current opinion in pharmacology 2005 Turner N, Tutt A, Ashworth A
• BRCA1 and BRCA2 as ovarian cancer susceptibility genes.
  Carcinogenesis 2005 Sowter HM, Ashworth A
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
  Nature 2005 Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A
• Receptor and secreted targets of Wnt-1/beta-catenin signalling in mouse mammary epithelial cells.
  BMC cancer 2005 Kenny PA, Enver T, Ashworth A
• Hallmarks of 'BRCAness' in sporadic cancers.
  Nature reviews. Cancer 2004 Turner N, Tutt A, Ashworth A
• DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells.
  EMBO reports 2004 Gudmundsdottir K, Lord CJ, Witt E, Tutt AN, Ashworth A
• BRCA2 in meiosis: turning over a new leaf.
  Trends in cell biology 2004 Gudmundsdottir K, Ashworth A
• Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way.
  Biochimica et biophysica acta 2004 Santarosa M, Ashworth A
• Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways.
  Human molecular genetics 2004 Hussain S, Wilson JB, Medhurst AL, Hejna J, Witt E, Ananth S, Davies A, Masson JY, Moses R, West SC, de Winter JP, Ashworth A, Jones NJ, Mathew CG
• Stem cells and breast cancer: A field in transit.
  Nature reviews. Cancer 2003 Smalley M, Ashworth A
• Close relatives or distant cousins?
  The Lancet. Oncology 2003 Tutt A, Ashworth A
• Phenotypic effects of heterozygosity for a BRCA2 mutation.
  Human molecular genetics 2003 Warren M, Lord CJ, Masabanda J, Griffin D, Ashworth A
• Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
  Human molecular genetics 2003 Hussain S, Witt E, Huber PA, Medhurst AL, Ashworth A, Mathew CG
• New biology of the oestrogen receptor.
  Lancet (London, England) 2003 Dowsett M, Ashworth A
• Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1.
  Oncogene 2003 Spicer J, Rayter S, Young N, Elliott R, Ashworth A, Smith D
• A targeted deletion in the endocytic receptor gene Endo180 results in a defect in collagen uptake.
  EMBO reports 2003 East L, McCarthy A, Wienke D, Sturge J, Ashworth A, Isacke CM
• A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein.
  The EMBO journal 2003 Foray N, Marot D, Gabriel A, Randrianarison V, Carr AM, Perricaudet M, Ashworth A, Jeggo P
• Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity.
  Oncogene 2003 Tutt A, Connor F, Bertwistle D, Kerr P, Peacock J, Ross G, Ashworth A
• X-chromosome inactivation: X marks the spot for BRCA1.
  Current biology : CB 2003 Stone C, McCabe N, Ashworth A
• The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.
  Trends in molecular medicine 2002 Tutt A, Ashworth A
• Functional and molecular characterisation of mammary side population cells.
  Breast cancer research : BCR 2002 Alvi AJ, Clayton H, Joshi C, Enver T, Ashworth A, Vivanco Md, Dale TC, Smalley MJ
• Retroviral vectors for establishing tetracycline-regulated gene expression in an otherwise recalcitrant cell line.
  BMC molecular biology 2002 Kenny PA, Enver T, Ashworth A
• MAP kinase phosphatases.
  Genome biology 2002 Theodosiou A, Ashworth A
• Biomedicine. D-Day for BRCA2.
  Science (New York, N.Y.) 2002 Witt E, Ashworth A
• Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation.
  EMBO reports 2002 Tutt AN, van Oostrom CT, Ross GM, van Steeg H, Ashworth A